Atsushi Oda
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Atsushi Oda has a total of 41 co-authors. Here are the top co-authors by number of shared publications:
- Hiroshi Miyazaki
Innovative Drug Research Laboratories, Research Division, and
2 shared publications Hiroyoshi Fujita
2 shared publications- Ikuo Wada
Department of Cell Science, Institute of Biomedical Sciences Fukushima Medical University School of Medicine Fukushima Japan
2 shared publications Katsuya Okawa
2 shared publicationsKazuhiko Matsuno
2 shared publicationsTakashi Kato
Kirin Brewery Co. Ltd, Pharmaceutical Research Laboratory, Maebashi, Gumma, Japan
2 shared publications
Latest Publications
- 15 April 2005
- Published by American Society of Hematology in Blood
- Vol. 105 (8) , 3141-3148
WAVE/Scars in platelets
Using specific antibodies against isoforms of WAVE (WASP [Wiskott-Aldrich syndrome protein] family Verprolin-homologous protein, also called Scar), we demonstrated that human platelets express all 3 isoforms. With the use of an in vitro pull-down technique, the src homology 3 (SH3) domain of insulin receptor substrate p53 (IRSp53) precipitated WAVE2 from platelet lysates more efficiently than did profilin I. The opposite was true for WAVE1, and neither precipitated WAVE3, suggesting that WAVE isoforms have different affinities to these ligands, while the SH3 domain of abl binds to all 3 isoforms. The 3 WAVE isoforms were distributed in the actin-rich Triton X-100–insoluble pellets following platelet aggregation induced by thrombin receptor–activating peptide. We also found that all 3 WAVE isoforms are substrates for calpain in vivo and in vitro. Although portions of these 3 isoforms were commonly distributed in the actin- and actin-related protein 2 and 3 (Arp2/3)–rich edge of the lamellipodia in spreading platelets, only WAVE2 remained in the cell fringe following detergent extraction or fixation of the cells. Finally, by mass spectrometry, we found that the proteins, which reportedly interact with WAVE/Scars, are present in platelets. These data suggest that the 3 WAVE isoforms exhibit common and distinct features and may potentially be involved in the regulation of actin cytoskeleton in platelets.
- 15 April 2005
- Published by American Society of Hematology in Blood
- Vol. 105 (8) , 3141-3148
WAVE/Scars in platelets
Using specific antibodies against isoforms of WAVE (WASP [Wiskott-Aldrich syndrome protein] family Verprolin-homologous protein, also called Scar), we demonstrated that human platelets express all 3 isoforms. With the use of an in vitro pull-down technique, the src homology 3 (SH3) domain of insulin receptor substrate p53 (IRSp53) precipitated WAVE2 from platelet lysates more efficiently than did profilin I. The opposite was true for WAVE1, and neither precipitated WAVE3, suggesting that WAVE isoforms have different affinities to these ligands, while the SH3 domain of abl binds to all 3 isoforms. The 3 WAVE isoforms were distributed in the actin-rich Triton X-100–insoluble pellets following platelet aggregation induced by thrombin receptor–activating peptide. We also found that all 3 WAVE isoforms are substrates for calpain in vivo and in vitro. Although portions of these 3 isoforms were commonly distributed in the actin- and actin-related protein 2 and 3 (Arp2/3)–rich edge of the lamellipodia in spreading platelets, only WAVE2 remained in the cell fringe following detergent extraction or fixation of the cells. Finally, by mass spectrometry, we found that the proteins, which reportedly interact with WAVE/Scars, are present in platelets. These data suggest that the 3 WAVE isoforms exhibit common and distinct features and may potentially be involved in the regulation of actin cytoskeleton in platelets.
- 1 July 2004
- Vol. 76 (7) , 651-4
[Mass spectrometry for platelet biochemistry].
- Open Access
- 1 February 2003
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 278 (8) , 6456-6460
CrkL Directs ASAP1 to Peripheral Focal Adhesions
- 1 February 2003
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 278 (8) , 6456-6460
Open AccessCrkL Directs ASAP1 to Peripheral Focal Adhesions
- 1 May 1999
- Published by Wiley in British Journal of Haematology
- Vol. 105 (2) , 382-387
Serum thrombopoietin and erythropoietin levels in patients with acute promyelocytic leukaemia during all-trans retinoic acid treatment
- 1 May 1999
- Published by Wiley in British Journal of Haematology
- Vol. 105 (2) , 382-387
Serum thrombopoietin and erythropoietin levels in patients with acute promyelocytic leukaemia during all-trans retinoic acid treatment
- 1 January 1999
- Published by Georg Thieme Verlag KG in Thrombosis and Haemostasis
- Vol. 82 (08) , 377-384
Thrombopoietin-Induced Signal Transduction and Potentiation of Platelet Activation
The presence of thrombopoietin, a humoral regulator of megakaryopoiesis and thrombopoiesis, had been suggested for years,1 however, some investigators were skeptical about the existence of such a factor. Modern studies of thrombopoietin begin with the cloning of c-mpl (the cellular counterpart of the v-mpl oncogene) and its cognate ligand genes. Following the cloning of the c-mpl proto-oncogene,2 Methia et al3 found that, in the presence of oligonucleotides antisense to the gene, CD34+ cells developed into megakaryocytic precursors less efficiently. As the development into other lineage was nearly intact, it was reasonably argued that the c-mpl protein may be the receptor for a thrombopoietin-like factor.3 This study inspired numerous investigations, which culminated in the cloning of the thrombopoietin gene in 1994.1, 4-8
- 1 January 1999
- Published by Georg Thieme Verlag KG in Thrombosis and Haemostasis
- Vol. 82 (08) , 377-384
Thrombopoietin-Induced Signal Transduction and Potentiation of Platelet Activation
The presence of thrombopoietin, a humoral regulator of megakaryopoiesis and thrombopoiesis, had been suggested for years,1 however, some investigators were skeptical about the existence of such a factor. Modern studies of thrombopoietin begin with the cloning of c-mpl (the cellular counterpart of the v-mpl oncogene) and its cognate ligand genes. Following the cloning of the c-mpl proto-oncogene,2 Methia et al3 found that, in the presence of oligonucleotides antisense to the gene, CD34+ cells developed into megakaryocytic precursors less efficiently. As the development into other lineage was nearly intact, it was reasonably argued that the c-mpl protein may be the receptor for a thrombopoietin-like factor.3 This study inspired numerous investigations, which culminated in the cloning of the thrombopoietin gene in 1994.1, 4-8